Trending...
- Roofman USA Expands Roofing Services Across Michigan, Adding Key Locations - 173
- Green Office Partner Named #1 Best Place to Work in Chicago by Crain's for 2025 - 160
- "Leading From Day One: The Essential Guide for New Supervisors" Draws from 25+ Years of International Management Experience - 151
April 13, 2021
Contact: Lynn Sutfin, 517-241-2112
LANSING, Mich. - Based on recommendations from Food and Drug Administration (FDA) and Centers for Disease Control and Prevention (CDC), the Michigan Department of Health and Human Services is asking that all Michigan providers temporarily pause the administration of Johnson & Johnson (J&J) vaccine in Michigan.
This temporary recommendation is based on the identification of six reported U.S. cases of a rare and severe type of blood clot in individuals after receiving the Johnson & Johnson vaccine. In these cases, a type of blood clot called cerebral venous sinus thrombosis was seen in combination with low levels of blood platelets (thrombocytopenia). These adverse reactions appear to be extremely rare, as more than 6.8 million doses of the Johnson & Johnson vaccine have been administered in the United States as of April 12, with nearly 200,000 of those doses administered in Michigan.
Vaccine providers across the state have been instructed not to administer this vaccine at this time, while the CDC and FDA review further data and assure that clinicians are identifying and reporting any potential adverse reaction. Clinics that are scheduled to administer Johnson & Johnson vaccine will either reschedule or use a different vaccine.
"More than 6.8 million doses of the Johnson & Johnson vaccine have been administered in the U.S., and these adverse events appear to be extremely rare. However, out of an abundance of caution, we are following recommendations from FDA and CDC and pausing the use of the Johnson & Johnson vaccine in Michigan," said Dr. Joneigh Khaldun, chief medical executive and chief deputy for health. "As we learn more about this from our federal partners, we will update vaccine providers and Michiganders across the state. We encourage everyone to continue making appointments to be vaccinated with the safe and effective Pfizer and Moderna COVID-19 vaccines at this time. These vaccines are the way we are going to end this pandemic as quickly as possible and move toward a sense of normalcy."
More on Michimich.com
All six cases occurred among women between the ages of 18 and 48, and symptoms occurred six to 13 days after vaccination. Treatment of this specific type of blood clot is different from the treatment that might typically be administered. Usually, an anticoagulant drug called heparin is used to treat blood clots. In this setting, administration of heparin may be dangerous, and alternative treatments need to be given.
CDC will convene a meeting of the Advisory Committee on Immunization Practices on Wednesday to further review these cases and assess their potential significance. FDA will review that analysis as it also investigates these cases.
Until that process is complete, CDC and FDA are recommending a pause in the use of this vaccine. This is important, in part, to ensure that the health care provider community is aware of the potential for these adverse events, and can plan for proper recognition and management due to the unique treatment required with this type of blood clot.
People who have received the Johnson & Johnson vaccine who develop severe headache, abdominal pain, leg pain or shortness of breath within three weeks after vaccination should contact their health care provider. Health care providers are asked to report adverse events to the Vaccine Adverse Event Reporting System at https://vaers.hhs.gov/reportevent.html.
Safety is the first priority in vaccine authorization or approval. The FDA has authorized the emergency use of COVID-19 vaccines after determining the vaccines meet FDA requirements. All of the authorized COVID-19 vaccines were found to be safe and effective in reducing the risk of severe illness, hospitalizations and death as caused by the virus. A robust process is in place to ensure the safety of any vaccine authorized or approved for use. More information about the safety of the COVID-19 vaccine is available at the CDC Vaccine Benefits website and the CDC Vaccine Safety website.
More on Michimich.com
To find a vaccination location and schedule an appointment, visit the Michigan.gov/Coronavirus website or the CDC COVID Vaccine Finder.
Michigan residents seeking more information about the COVID-19 vaccine can visit Michigan.gov/COVIDvaccine. Information around this outbreak is changing rapidly. The latest information is available at Michigan.gov/Coronavirus and CDC.gov/Coronavirus.
Contact: Lynn Sutfin, 517-241-2112
LANSING, Mich. - Based on recommendations from Food and Drug Administration (FDA) and Centers for Disease Control and Prevention (CDC), the Michigan Department of Health and Human Services is asking that all Michigan providers temporarily pause the administration of Johnson & Johnson (J&J) vaccine in Michigan.
This temporary recommendation is based on the identification of six reported U.S. cases of a rare and severe type of blood clot in individuals after receiving the Johnson & Johnson vaccine. In these cases, a type of blood clot called cerebral venous sinus thrombosis was seen in combination with low levels of blood platelets (thrombocytopenia). These adverse reactions appear to be extremely rare, as more than 6.8 million doses of the Johnson & Johnson vaccine have been administered in the United States as of April 12, with nearly 200,000 of those doses administered in Michigan.
Vaccine providers across the state have been instructed not to administer this vaccine at this time, while the CDC and FDA review further data and assure that clinicians are identifying and reporting any potential adverse reaction. Clinics that are scheduled to administer Johnson & Johnson vaccine will either reschedule or use a different vaccine.
"More than 6.8 million doses of the Johnson & Johnson vaccine have been administered in the U.S., and these adverse events appear to be extremely rare. However, out of an abundance of caution, we are following recommendations from FDA and CDC and pausing the use of the Johnson & Johnson vaccine in Michigan," said Dr. Joneigh Khaldun, chief medical executive and chief deputy for health. "As we learn more about this from our federal partners, we will update vaccine providers and Michiganders across the state. We encourage everyone to continue making appointments to be vaccinated with the safe and effective Pfizer and Moderna COVID-19 vaccines at this time. These vaccines are the way we are going to end this pandemic as quickly as possible and move toward a sense of normalcy."
More on Michimich.com
- New Leadership and Renovations Usher in Next Chapter for Sunrise Manor
- Who Will Win the 2025 WNBA Finals? OddsTrader Shares Live Betting Odds and Projections
- Geeks5g Creative Marketing: The Powerhouse Behind Business Growth
- Two new inductees selected to the Trenton Educational Foundation's Wall of Fame
- Agemin Unveils Breakthrough AI Model for Biometric Age Estimation, Setting New Standards in Online Child Safety
All six cases occurred among women between the ages of 18 and 48, and symptoms occurred six to 13 days after vaccination. Treatment of this specific type of blood clot is different from the treatment that might typically be administered. Usually, an anticoagulant drug called heparin is used to treat blood clots. In this setting, administration of heparin may be dangerous, and alternative treatments need to be given.
CDC will convene a meeting of the Advisory Committee on Immunization Practices on Wednesday to further review these cases and assess their potential significance. FDA will review that analysis as it also investigates these cases.
Until that process is complete, CDC and FDA are recommending a pause in the use of this vaccine. This is important, in part, to ensure that the health care provider community is aware of the potential for these adverse events, and can plan for proper recognition and management due to the unique treatment required with this type of blood clot.
People who have received the Johnson & Johnson vaccine who develop severe headache, abdominal pain, leg pain or shortness of breath within three weeks after vaccination should contact their health care provider. Health care providers are asked to report adverse events to the Vaccine Adverse Event Reporting System at https://vaers.hhs.gov/reportevent.html.
Safety is the first priority in vaccine authorization or approval. The FDA has authorized the emergency use of COVID-19 vaccines after determining the vaccines meet FDA requirements. All of the authorized COVID-19 vaccines were found to be safe and effective in reducing the risk of severe illness, hospitalizations and death as caused by the virus. A robust process is in place to ensure the safety of any vaccine authorized or approved for use. More information about the safety of the COVID-19 vaccine is available at the CDC Vaccine Benefits website and the CDC Vaccine Safety website.
More on Michimich.com
- Strategic Partnerships with Defiant Space Corp and Emtel Energy USA Powerfully Enhance Solar Tech Leader with NASA Agreements: Ascent Solar $ASTI
- 120% Revenue Surge with Four Straight Profitable Quarters Signal a Breakout in the Multi-Billion Dollar Homebuilding Market: Innovative Designs $IVDN
- Leading Venture Capital Firms Recognize Wzzph Exchange's Technical Architecture and Security Framework as Industry Benchmark
- DivX Unveils Major DivX Software Update: Seamless Video Sharing and Customizable Playback Now Available
- Nespolo Mechanical Helps New Mexico Families Save Thousands on Heating Costs This Fall
To find a vaccination location and schedule an appointment, visit the Michigan.gov/Coronavirus website or the CDC COVID Vaccine Finder.
Michigan residents seeking more information about the COVID-19 vaccine can visit Michigan.gov/COVIDvaccine. Information around this outbreak is changing rapidly. The latest information is available at Michigan.gov/Coronavirus and CDC.gov/Coronavirus.
0 Comments
Latest on Michimich.com
- Comerica Incorporated Names Kristina Janssens Senior Executive Vice President and Chief Risk Officer
- ENTOUCH Completes $50 million Funding Round
- Teaming Agreement with Emtel Energy USA to Advance Thin-Film PV Energy Storage Capabilities; NASA agreements for Solar Space Tech; Ascent Solar $ASTI
- Nebuvex Acknowledges Platform "Too Secure" for Anonymous Traders; Institutional Investors Disagree
- From Tokyo to Berlin: FreeTo.Chat Unites Cultures with the World's First Confession VRX — EmojiStream™
- AZETHIO Launches Multi-Million Dollar User Protection Initiative Following Unprecedented Platform Growth
- Matecrypt Observes South American Cryptocurrency Adoption Surge Amid Economic Shifts
- Assent Uncovers Over 695 Unique PFAS Across Global Supply Chains as Regulations Increase
- Cryptocurrency Quarterly Trading Volume Surpasses $15 Trillion Record High as BrazilNex Acknowledges Industry 'Growing Pains' Amid Market Speculation
- AHRFD Initiates Legal Proceedings Against Anwalt.de for Publishing Defamatory and False Content
- New Analysis Reveals the Complex Forces Driving the 'Great Human Reshuffle'
- Elevate Unveils GroundComm X30 at 2025 International GSE Expo in Las Vegas
- NEW power supply release from Kepco Dynatronix - HSP Advanced
- St. Augustine Honors Hispanic Heritage Month
- Vesica Health Receives AUA Guideline Inclusion
- Steward's Plumbing Sponsors the 2025 Samson Challenge, Bringing Community, Fitness, and Fun Together in Albuquerque
- Spelman College wins 7th annual Moguls in the Making entrepreneurial pitch competition
- Price Right RV Announces Participation in the 36th Annual Fall Detroit RV & Camping Show
- 10xLaw.com Extends Employment Opportunity to Kim Kardashian
- DecisionPoint Technologies Accelerates Growth with Acquisition of Acuity Technologies